L-Leucine of veterinary-grade API specification does not behave uniformly across the dosage-form routes requested for animal therapy and nutrition. The α-amino and α-carboxyl groups ionise at 2.36 and 9.60; the isoelectric point is 5.98. Solubility in purified water is approximately 23–24 g/L at 25 °C, which imposes immediate constraints on high-concentration injectable dosage forms. In the dry state, the crystal habit is frequently described as plate-like or flaky, and the material can act as a glidant or anti-adherent at low levels while creating sticking and lamination at high tablet dose fractions. These properties determine whether a granulation step is mandatory, whether terminal sterilisation can be validated, and whether a premix can remain homogeneous from mixer to feed mill bin.

Direct compression of L-leucine at dose fractions above 40–50 % w/w of the tablet core is rarely robust on high-speed rotary presses because the unmodified crystals show poor plastic deformation and a marked sensitivity to residual moisture. Production experience on D-tooling machines running at 40–80 rpm indicates that unmodified leucine tablets tend toward capping when main compression force exceeds 18–22 kN without adequate binder. The preferred route is therefore wet granulation in a high-shear mixer at impeller 200–350 rpm and chopper 1500–2500 rpm for 4–8 min, using an aqueous binder solution of povidone K30 at 3–5 % w/w of dry granulate. A disintegrant such as crospovidone or sodium starch glycolate at 3–6 % w/w is added intragranularly and extragranularly in approximately equal portions to keep disintegration below 15 min in 0.1 N HCl at 37 °C under USP <711> or Ph. Eur. 2.9.3. After drying at 45–55 °C to a loss on drying of 1.5–2.5 %, the granules are milled through an 0.8 mm screen and lubricated with magnesium stearate 0.5–1.0 % w/w for 2–4 min. Final blend uniformity is verified by USP <905> or Ph. Eur. 2.9.40; acceptance values outside 15 require re-blending or geometric dilution correction. The resulting tablets, typically 100 mg, 250 mg, or 500 mg leucine strength for companion-animal nutritional support, are characterised by friability <1.0 % under Ph. Eur. 2.9.7 and hardness 60–120 N depending on tablet shape and break-line. Coating with hydroxypropyl methylcellulose in a side-vented pan at 60–70 °C bed temperature improves moisture resistance, but coating weight gain must not exceed 2–4 % w/w because additional film thickness delays disintegration beyond the specification window. For chewable veterinary tablets, leucine is often blended with liver powder or yeast-based palatants before granulation; these nitrogen-rich carriers increase the risk of Maillard browning during drying, so the inlet air dew point is kept below 5 °C and product temperature below 50 °C.

What Limits Leucine Loading in Terminal-Sterilised Parenteral Amino Acid Solutions for Ruminant Adjunctive Nutrition?

For injectable products, L-leucine is generally processed as a component of a mixed amino acid solution rather than as a single-entity injection, because its aqueous solubility falls to approximately 23–24 g/L at 25 °C. Terminal sterilisation by saturated steam at 121 °C for 15 min is feasible only when the formulation pH is adjusted to 5.5–7.0 with dilute hydrochloric acid or sodium hydroxide and when reducing sugars such as dextrose are absent from the same heat-load. Autoclaving leucine in the presence of dextrose produces measurable browning products; the degradation rate is pH-, time-, and sugar-concentration dependent, and published data for this specific formulation is limited. Production-scale compounding uses cooled water for injection at 15–20 °C under nitrogen overlay, with dissolution completed in a closed jacketed vessel equipped with a bottom-mounted magnetic stirrer operating at 100–200 rpm. After pH adjustment, the solution is passed through a 0.45 µm clarifying filter and then two validated 0.22 µm sterilising-grade filters in series before aseptic filling into Type I borosilicate glass vials or multilayer non-PVC bags. Filling lines for heat-sterilised solutions are commonly validated to fill volumes from 250 mL to 1000 mL with a fill-weight accuracy of ±1.0 %. The finished product must satisfy USP <71> sterility, USP <85> bacterial endotoxin limits, USP <788> or Ph. Eur. 2.9.19 particulate matter requirements, and Ph. Eur. 2.9.34 for extractable volume. For small-volume containers the common acceptance criteria are 6000 particles per container at ≥10 µm and 600 particles per container at ≥25 µm, while large-volume presentations are evaluated on a per-millilitre basis. Osmolality after dilution of the amino acid concentrate is critical for intravenous administration to calves and adult cattle, with peripheral infusion solutions usually adjusted to 280–320 mOsm/kg; leucine contributes to total osmolarity less than an equivalent mass of sodium chloride but more than an equivalent mass of glycine. The hydrophobic side-chain of leucine limits concentration in cold storage: batches stored at 2–8 °C for 24–72 h before terminal sterilisation can show precipitation if the pH drifts toward the isoelectric point 5.98. Consequently, pH is held at 6.0–6.5 during the hold period and validated by in-process sampling every 2 h. The sterile bulk hold time before filling is commonly limited to 8–12 h at 20–25 °C unless bioburden studies support a longer duration. For large animal use, the final product may be packed in 2 L or 5 L flexible bags, and the manufacturing process must demonstrate compatibility with the plasticiser system by Ph. Eur. 3.1.5 or USP <661.1> after storage at 40 °C / 75 % RH for 6 months. If the API is supplied as a sterile powder for reconstitution, the powder is lyophilised from a solution at 1–2 % w/w leucine concentration, with the freeze-drying cycle designed to keep the product temperature below the collapse temperature, typically -25 °C to -30 °C, and residual moisture below 2.0 %.

Capsule filling with L-leucine requires control of particle size distribution and moisture because the plate-like crystals can bridge in the hopper and produce erratic fill weights on dosator-type machines. For two-piece hard gelatin capsules in sizes 0 or 1, a direct fill of milled or granulated leucine is often feasible if the powder bed is conditioned to relative humidity 30–45 % before loading. High-humidity storage softens gelatin and causes sticking; prolonged dry conditions below 20 % RH make shells brittle and increase cracking during high-speed filling. HPMC capsules are less sensitive to low moisture but may show delayed dissolution in fasted carnivores if the fill contains hydrophobic leucine without a wetting agent. A standard veterinary capsule formula for equine or canine supplemental use contains the specified leucine dose, microcrystalline cellulose 10–20 % w/w, croscarmellose sodium 1–3 % w/w, and magnesium stearate 0.5 % w/w. The blend is passed through a 30-mesh screen and mixed in a V-blender at 25–30 rpm for 10–20 min. Fill-weight uniformity is assessed by Ph. Eur. 2.9.5 or USP <905>; capsule products intended for dietary supplement use may instead be verified by USP <2091> weight variation criteria. On filling machinery, tamping-pin machines require lower powder lubrication than dosator systems because the powder is compressed into a plug inside the body; tamping pressures of 50–150 N are typical for size 1 capsules with 300–500 mg fill weight. Dissolution testing in USP apparatus 1 at 50 rpm using 900 mL of 0.1 N HCl at 37 °C is used to confirm release; gelatin capsules containing leucine/microcrystalline cellulose blends generally release at least 80 % within 30 min, while HPMC capsules may require 45–60 min and are therefore less preferred for acute metabolic support. The finished capsules are packed in HDPE bottles with a desiccant when intended for tropics, and stability zones IVb at 30 °C / 75 % RH demand accelerated testing at 40 °C / 75 % RH for 6 months before long-term batch release.

Premix Carrier Selection and Mixer Validation Under 21 CFR 225.65 and 225.80

Leucine intended for medicated feed or nutritional premix use is rarely added as a neat powder because the dose per metric tonne is too low for direct addition and segregation risk is high. A typical leucine premix is manufactured on a carrier such as calcium carbonate, corn cob granules, rice hulls, or wheat middlings, with leucine inclusion between 1 % and 10 % w/w depending on the final feed inclusion rate. The first production step is not mixing but carrier conditioning: carriers are dried to <10 % moisture and screened to a particle size band, often 106–850 µm, so that leucine particles adhere to the carrier surface rather than separating by density. In a horizontal ribbon mixer with a working capacity of 60–70 % of gross volume, the carrier is charged first and vegetable oil or mineral oil is added at 0.5–1.5 % w/w as a binder and dust suppressant. Leucine is then added through a 20-mesh safety screen and mixed for 10–15 min after the minor components. Mixer validation follows 21 CFR 225.80 requirements for production and control procedures and 21 CFR 225.65 equipment cleanout procedures; sampling is performed at 10 or more locations, with assay results expected to show a relative standard deviation below 5 % for the active marker. Carryover limits for subsequent batches are measured by feeding flush batches of untreated carrier through the mixer and assaying for leucine; in many mill validation protocols, residual leucine in the flush is required to fall below 2.5 % of the previous batch potency when measured by HPLC with UV or fluorescence detection. If leucine is the only active in the premix, simple nitrogen analysis is not specific because carrier proteins and moisture will interfere; the validated release method is therefore ion-pairing HPLC with a C18 column or pre-column derivatisation with 9-fluorenylmethyl chloroformate. The finished premix is filled into multi-wall paper or woven polypropylene bags with polyethylene liners, labelled under 21 CFR 225.40, and stored below 25 °C and 60 % RH. For the European market, the same premix falls under Regulation (EU) 2019/4 for medicated feed and must comply with the feed hygiene requirements of Regulation (EC) No 183/2005; cross-contamination documentation follows the homogeneous distribution provisions applied to the mill’s hazard analysis and critical control point plan. A principal failure mode on production scale is electrostatic adhesion of fine leucine to mixer walls and dust extraction ducts, which can shift the first batches after line start by 2–5 % of nominal potency unless the mixer is grounded and the relative humidity is maintained above 40 %.

When L-leucine is dry-blended into oral electrolyte or nutritional powders for calves, foals, or poultry, the controlling variable is not only blend uniformity but the chemical stability of leucine in the presence of dextrose, lactose, and other reducing sugars. These sugars are common in oral rehydration sachets, and a simple V-blender cycle of 20–30 min at 25–30 rpm is sufficient for blend homogeneity when the leucine fraction is above 5 % w/w and the bulk powder has a mean particle size of 150–250 µm. However, the same formulation stored at 60 % RH and 30 °C can develop browning and free-amino acid loss within weeks if the water activity exceeds 0.4; the exact rate depends on reducing sugar content and temperature. Production lines therefore use sachet materials with moisture vapour transmission rate below 0.5 g/m²/day at 38 °C / 90 % RH, and the powder is filled to a headspace oxygen concentration below 3 % when the pouch includes an oxygen scavenger. The powder itself is milled through an 0.5 mm screen and blended at room temperature; sodium chloride, potassium chloride, and sodium bicarbonate are commonly present, and these electrolytes do not directly degrade leucine but increase the ionic strength of any free moisture layer on the powder surface, which can accelerate the reduction of glass transition temperature in amorphous regions. Because leucine is hydrophobic, its wetting in reconstituted oral solutions is improved by reducing the particle size to D90 < 100 µm or by co-processing with citric acid and sorbitol as dispersing agents. A typical calf oral powder contains leucine at 2–5 g per single-dose sachet of 100–150 g, and the mixture is reconstituted with 2 L of warm water at 38–40 °C immediately before dosing. In poultry water medication, leucine is often included at 0.5–1.0 g/L of drinking water; the powder premixture must pass through a 60-mesh screen before distribution into water proportioners to ensure the low-solubility leucine does not settle in stock solutions. Final powder batches are tested for loss on drying by Ph. Eur. 2.2.32 or USP <731>, and moisture is maintained below 2.0 %. For food-producing species, the active substance specification is reconciled with the residue and withdrawal provisions of the intended regulatory region, but leucine as an amino acid nutrient is generally classified outside antibiotic residue controls in major markets.

When L-Leucine Is Agglomerated with Povidone K30 in a Top-Spray Fluidised Bed

Fluidised-bed granulation is selected over high-shear wet granulation when the final dosage form requires low friability, rapid dispersal in water, or improved flow into high-speed capsule and sachet lines. In a top-spray configuration, the leucine powder is pre-blended with fillers such as lactose monohydrate or mannitol and then fluidised at inlet air temperature 55–75 °C; product temperature is held at 34–42 °C by adjusting spray rate and inlet humidity. The binder solution is typically povidone K30 dissolved in purified water at 5–10 % w/w, sprayed through a two-fluid nozzle with atomising air pressure 0.8–1.5 bar and spray rate 15–30 g/min per kg of starting powder. The end-point is not determined by a single moisture value; operators monitor pressure drop across the filter bags and outlet air relative humidity until the granule median particle size reaches 200–400 µm. Over-wetting produces agglomerates above 850 µm and increases drying time, while under-wetting generates fines that segregate later in a tablet press or sachet filler. Drying continues at 60–70 °C until loss on drying is 1.0–2.0 %. The dried granules are screened through 1.0 mm and 0.150 mm sieves to remove overs and fines; acceptable yield is generally 75–90 % of the product mass between the two screens, and the oversized fraction is returned to a low-shear mill. Particle-size distribution is tested by Ph. Eur. 2.9.12 or USP <786>, and flow is measured with a shear cell according to ASTM D6682 or D6773. A flow function coefficient below 4 indicates cohesive behaviour and requires either a glidant or a further agglomeration pass; values above 7 are typically sufficient for automated filling. Bulk density after granulation may range from 0.45 g/mL to 0.65 g/mL, and this affects sachet fill volume more than capsule weight. For water-dispersible granules used in poultry drinking lines, the granule must wet rapidly without forming a floating hydrophobic layer; the addition of poloxamer 188 at 0.5–1.0 % w/w to the binder solution reduces surface tension and promotes wetting of the leucine surface. Reconstituted dispersions are evaluated by visual retention on a 75 µm sieve after stirring in 2 L of water at 20–25 °C for 5 min; undissolved leucine residual should be below 5 % of label dose. The finished granules are packed in triple-layer foil or PET/AL/PE sachets to maintain water activity below 0.4. This dosage form is commonly used for swine top-dress or oral drenching after reconstitution, with leucine content per sachet from 2 g to 20 g depending on species and production stage.

Formulating L-leucine as a ready-to-use oral drench for cattle or sheep exposes the solubility limit more directly than dry powder formats because the target dose must remain in solution at ambient farm temperatures. At 25 °C, the maximum single-solute concentration in water is approximately 23–24 g/L, but commercial drench products rarely exceed 15–20 g/L to avoid crystallisation during cold storage at 5 °C. The pH of a saturated leucine solution is close to the isoelectric point 5.98, where the zwitterionic form dominates and ionisation is minimal. To increase solubility, the solution is acidified to pH 3.5–4.0 with dilute hydrochloric acid, which raises the proportion of the cationic form; the resulting solution is buffered with citrate or acetate to prevent drift. However, acidified drench solutions are unpalatable to ruminants and may require addition of sodium bicarbonate immediately before dosing to neutralise the formulation in the drenching gun reservoir. In a typical batching vessel, purified water is heated to 40–50 °C to accelerate dissolution, leucine is added under recirculation through a 10 µm filter housing, and the batch is cooled to 20–25 °C before final volume adjustment. For multi-dose HDPE or PET containers, the preservative system is selected to meet Ph. Eur. 5.1.3 antimicrobial efficacy; benzyl alcohol at 0.5–1.0 % v/v or potassium sorbate at 0.1–0.2 % w/v is common, but compatibility with the acidic pH and the amino acid must be verified by assay over 12–24 months. The finished product is tested for pH, density, refractive index, leachable organic carbon, and microbiological quality under Ph. Eur. 2.6.12 and 2.6.13. If the product is indicated for neonatal calves or lambs, the osmolality of the single-dose drench is usually adjusted with sorbitol or glycerol to 500–700 mOsm/kg for oral tolerance; hypertonic solutions above 1000 mOsm/kg can delay abomasal emptying and provoke diarrhoea. Production-scale filling uses peristaltic pumps with a dose accuracy of ±2 % for volumes from 10 mL to 50 mL. A key operational boundary is that leucine solutions should not be mixed with strong oxidising disinfectants, and alkaline cleaning agents must be rinsed completely because residual sodium hydroxide can regenerate the neutral zwitterion and cause precipitation on tank walls and filling needles.